Terbium-161 NCA
GMP grade available
Terbium-161 in aqueous 0.05M HCl is compliant to the highest quality standards of Good Manufacturing Practice (GMP).
Carrier-free lanthanide (NCA) Terbium-161 is produced by neutron activation of enriched Gadolinium-160 using small and medium research reactors.
As a promising radionuclide for Radioligand Therapy, Terbium-161 exhibits comparable chemical characteristics to known radiolanthanides and providing for a bioequivalence creating a similar biodistribution, however a higher cellular absorbed dose is given to lesions and (micro)metastases.
Radiochemistry Unchanged
Terbium-161 provides for comparable chemical characteristics to known radiolanthanides, allowing the utilization of current radiolabeling techniques, but enabling a higher cellular absorbed dose.
Imaging Optimized
Allowing optimization of the SPECT reconstruction parameters, Terbium-161 may provide for higher spatial resolution SPECT imaging, leading to the detection of smaller lesions that provides input for a further optimized treatment plan.
Radiation Safety Improved
Terbium-161 provides for an immediate decrease in dose rate allowing for a significant improvement in general radiation safety. This optimization of radiation safety may extend current treatment room capacity for Radioligand Therapy or allow for outpatient treatment.
Latest news
- Publishing date:
Join Us at EANM in Vienna, Booth #321, Hall X3
From October 17–21, the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) will take place in Vienna.
This year, we have exciting developments to share. We are eager to present the latest clinical advancements of Terbium-161, including the first evidence demonstrating the superiority of Tb-161. Furthermore, we will provide exclusive insights into our newly established production facility, which is fully dedicated to securing the future supply of Tb-161.
You are warmly invited to visit us at Booth #321, Hall X3. Our team will be on hand to show you our latest progress and discuss how we can best support your projects. We look forward to welcoming you in Vienna!
- Publishing date:
New Meta-Analysis: [161Tb]Tb-PSMA Outperforms Standard RLT in Advanced Prostate Cancer
A landmark study published in Frontiers in Medicine by Albano, Paone, and Treglia delivers critical clinical validation for hospitals looking to adopt next-generation radioligand therapy. As the first-ever systematic review and meta-analysis of its kind, the study analyzed data from 80 metastatic castration-resistant prostate cancer (mCRPC) patients across 291 cycles. It conclusively proves that Terbium-161 (Tb-161) is not only highly effective but also exceptionally safe.
The clinical outcomes provide a compelling case for nuclear medicine departments. The pooled analysis demonstrated a remarkable 83.9% disease control rate and a 50.2% objective PSA response rate. Crucially, this high efficacy was maintained in late-stage patients who had previously failed conventional Lutetium-177 or Actinium-225 therapies, proving that Tb-161 can overcome established resistance pathways. Despite this powerful therapeutic effect, severe side effects were rare, confirming that the treatment fits safely and seamlessly into existing outpatient and inpatient hospital workflows.
This clinical advantage is driven by the unique physics of Terbium-161. By co-emitting medium-range beta particles and short-range Auger and conversion electrons, it delivers a massive, highly localized energy dose. This dual action successfully eradicates single cancer cells and micrometastases that traditional beta-only emitters often miss. Since Terbium-161 shares identical chelator chemistry with Lutetium-177, your hospital can easily adopt these protocols using your existing radiopharmacy infrastructure. Partner with TerThera today to secure a reliable, commercial-scale supply of high-purity Terbium-161 for your clinic.
- Publishing date:
TerThera reached the next milestone producing over 25,000GBq (675Ci) Terbium-161
TerThera B.V. has achieved a major new milestone by producing over 25,000 GBq (675 Ci) of Terbium-161. Thanks to this record-breaking production, the crucial precursor is now available in abundance on a full global scale, supplying clinical trials and multiple R&D pipelines across six continents. Since its launch in 2022, TerThera has been fully dedicated to making this isotope widely available, a mission that is now accelerated by a rapidly increasing demand from hospitals, biotech companies, and Big Pharma alike.
